{"title":"Retraction Notice: Silencing of Long Non-Coding RNA FGD5-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer by Regulating the miR-493-5p/DDX5 Axis.","authors":"","doi":"10.1177/15330338241311208","DOIUrl":"10.1177/15330338241311208","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241311208"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Zinc Finger Proteins in Colorectal Cancer: Insights into Molecular Mechanisms and Therapeutic Implications.","authors":"Chongyuan Lan, Ming Qiu, Minglin Lin","doi":"10.1177/15330338251334447","DOIUrl":"https://doi.org/10.1177/15330338251334447","url":null,"abstract":"<p><p>Colorectal cancer ranks as one of the most common malignancies globally, with mortality rates second only to lung cancer. Despite improvements in diagnostic and therapeutic approaches, long-term survival rates for colorectal cancer patients remain unsatisfactory. The onset and progression of this disease involve intricate molecular mechanisms, influenced by a range of biological factors. Zinc finger proteins play a critical role in these processes, impacting tumor development and patient prognosis. This review summarizes current research on zinc finger proteins in colorectal cancer, highlighting key findings and advancements in understanding their role in tumor biology.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251334447"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12032436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Circulating Immune Features Synergizing Neutrophil-to-Lymphocyte Ratio in Prediction of Poor Survival of Early-Stage Hepatocellular Carcinoma After Thermal Ablation.","authors":"Fangying Fan, Guoping Dong, Chuanhui Han, Yanchun Luo, Xin Li, Xuanjuan Dong, Zhen Wang, Ping Liang, Jie Yu","doi":"10.1177/15330338241309402","DOIUrl":"10.1177/15330338241309402","url":null,"abstract":"<p><p>Background and AimPredictors of neutrophil-to-lymphocyte ratio (NLR) and traditional clinical variables for hepatocellular carcinoma (HCC) prognosis after locoregional therapies were useful while exhibited modest prognostic performances. We dig out the potential of circulating immune features for HCC prognosis prediction.Methods244 patients with early-stage HCC who were treated with thermal ablation and performed the peripheral blood mononuclear cells (PBMCs) tests were included. Patients were randomly assigned in 3:1 ratio to discovery (n = 183) and validation (n = 62) sets. Three models, including clinical (Clin-model), NLR-Clin-model and Immune-NLR-Clin-model were constructed using Cox regression model. Concordance index (c-index), integrated discrimination improvement (IDI) and net reclassification improvement (NRI) were used for performance evaluation.ResultsThe Immune-NLR-Clin-model exhibited the best performance of 0.706 (95% CI:0.644-0.768) and 0.702 (95% CI:0.566-0.837) in discovery and validation sets, respectively. At 36-month prediction, the IDI and continuous-NRI show trend of improvement, with the IDI was 0.050 (95%CI: -0.5%-12.5%) (<i><b>P </b></i>< .0270) and the continuous-NRI was 0.147 (95%CI: -0.5%-36.6%) (<i><b>P </b></i>= .060) in discovery cohort. <b>Tre</b>g, C<b>D</b>8<sup>+</sup> and <b>N</b>LR from the immune-related combined model were selected to build <b>TREND</b> score. The median overall survival in TREND-low risk and high risk were 98.08 and 62.00 months, respectively (<b><i>P</i></b> < .0001). The discrimination ability approached significantly in validation set (<b><i>P</i></b> = .3200).ConclusionsCirculating immune features may be helpful components aiding NLR for HCC predictive models.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241309402"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Retraction notice: \"MicroRNA-199a Inhibits Cell Proliferation, Migration, and Invasion and Activates AKT/mTOR Signaling Pathway by Targeting B7-H3 in Cervical Cancer\".","authors":"","doi":"10.1177/15330338251343588","DOIUrl":"10.1177/15330338251343588","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251343588"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"R Spondin in Cancer: Inducer or Impeder?","authors":"Vishnu Pulavarthy, Rohit Gundamaraju","doi":"10.1177/15330338251327465","DOIUrl":"10.1177/15330338251327465","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251327465"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic Significance of Dynamic Lymphocyte Changes in Esophageal Cancer Patients Receiving Fluorouracil-Cisplatin Combined with Radiotherapy: A Systematic Review and Meta-Analysis.","authors":"Cong Zhang, Zhi Yang, Jie Li, Lina Zhao","doi":"10.1177/15330338251341431","DOIUrl":"10.1177/15330338251341431","url":null,"abstract":"<p><p>IntroductionChemoradiotherapy (CRT) is important to the esophageal cancer (EC) management. However, the predictive value of lymphocyte-related parameters, such as lymphocyte count (L), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), is not yet fully understood. Moreover, chemotherapy agents like fluorouracil and cisplatin may have an impact on lymphocyte dynamics. This meta-analysis aims to evaluate the prognostic value of these parameters in EC patients undergoing concurrent CRT (eg, radiotherapy combined with fluorouracil and cisplatin), particularly in the context of specific chemotherapy regimens.MethodsElectronic databases were comprehensively searched up to September 2023 for research that assesses the prognostic role of lymphocyte-related indicators in EC patients undergoing CRT. Combined Hazard Ratios (HR) were estimated with a random-effects model, supplemented by meta-regression and subgroup analyses for enhanced insights.ResultsOf the 41 studies selected for qualitative evaluation, 22 were eligible for meta-analysis. These results revealed that increased pre-NLR (HR = 1.87, 95% CI = 1.55-2.26), lower pre-LMR (HR = 1.94, 95% CI = 1.36-2.77), lower dur-L (HR = 1.56, 95% CI = 1.28-1.90), and higher post-NLR (HR = 1.95, 95% CI = 1.08-3.51) predicted poorer overall survival (OS). Lower pre-LMR (HR = 1.73, 95% CI = 1.14-2.65) and lower dur-L (HR = 1.39, 95% CI = 1.14-1.69) were significant predictors of worse progression-free survival (PFS). The predominant chemotherapy regimen analyzed was fluorouracil combined with cisplatin, which significantly influenced lymphocyte counts and ratios during treatment.ConclusionsOur meta-analysis indicates that pre-treatment NLR, pre-treatment LMR, during-treatment L, and post-treatment NLR are valuable prognostic biomarkers for EC undergoing CRT, particularly in those treated with fluorouracil and cisplatin. Further investigations are warranted to explore their prognostic implications and therapeutic potential.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251341431"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Corrado Ini', Pietro Valerio Foti, Renato Farina, Francesco Tiralongo, Davide Giuseppe Castiglione, Marta Cannarozzo, Corrado Spatola, Emanuele David, Stefano Palmucci, Andrea Russo, Giuseppe Broggi, Teresio Avitabile, Antonio Basile
{"title":"Percutaneous Locoregional Therapies for the Treatment of Liver Metastases from Uveal Melanoma: A Systematic Review.","authors":"Corrado Ini', Pietro Valerio Foti, Renato Farina, Francesco Tiralongo, Davide Giuseppe Castiglione, Marta Cannarozzo, Corrado Spatola, Emanuele David, Stefano Palmucci, Andrea Russo, Giuseppe Broggi, Teresio Avitabile, Antonio Basile","doi":"10.1177/15330338251343144","DOIUrl":"10.1177/15330338251343144","url":null,"abstract":"<p><p>IntroductionThe prognosis of patients with uveal melanoma is related to several factors, including local or extraocular extension of the disease. Up to 50% of the patients with initial diagnosis of uveal melanoma develop metastases within few years and the liver represents the main site of metastatic spread. Patients with metastatic disease have a generally poor prognosis and few treatment options are available. In the last decades, the role of interventional radiology has expanded the range of treatment options and different minimally invasive liver-directed therapies were developed for liver metastases from uveal melanoma. The purpose of our systematic review was to analyze and review techniques, outcomes and safety of targeted-liver minimally invasive therapies in patients with metastatic uveal melanoma.MethodsAccording to PRISMA criteria, an extensive literature research (including more than 1600 articles) was finalized to collect the main articles on minimally invasive therapies. Based on the inclusion and exclusion criteria, 26 studies were selected for inclusion in the present systematic review (20/26 articles were retrospective studies, 6/26 articles were prospective studies). We collected data on 955 patients underwent the following procedures: radioembolization, transcatheter arterial chemoembolization, transarterial immunoembolization, percutaneous hepatic perfusion and thermal therapies.ResultsAmong procedures analyzed, the median overall survival was 16 months, the median progression-free survival was 8.2 months, while the median overall response rate was 39%. Post-procedure haematologic and gastrointestinal adverse events were predominant after percutaneous hepatic procedures.ConclusionTo date, different minimally invasive therapies are available for the treatment of metastatic uveal melanoma. Studies on percutaneous liver-directed therapies have demonstrated improvement in outcomes, prolonging overall survival and progression-free survival, and with an acceptable safety profile.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251343144"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jun-Tao Tan, Lili Hu, Qi-Hua Jiang, Hai Hu, Zhi Yang, Zhi-Hua Li, Ping-Hua Hu
{"title":"CGRP, PD-1 and PD-L1 as Biomarkers for PICC-Related Bloodstream Infections in Breast Cancer Patients.","authors":"Jun-Tao Tan, Lili Hu, Qi-Hua Jiang, Hai Hu, Zhi Yang, Zhi-Hua Li, Ping-Hua Hu","doi":"10.1177/15330338251342877","DOIUrl":"10.1177/15330338251342877","url":null,"abstract":"<p><p>IntroductionPeripherally inserted central catheter (PICC)-related bloodstream infections (BSIs) are severe complications in breast cancer patients undergoing chemotherapy. This study evaluated the diagnostic potential of calcitonin gene-related peptide (CGRP), programmed cell death protein-1 (PD-1), and its ligand (PD-L1) as biomarkers for PICC-related BSIs.MethodsA total of 384 breast cancer patients with PICC placement were retrospectively identified from medical records, of these, 78 developed BSIs and 306 did not. Serum levels of CGRP, PD-1, and PD-L1 were measured using enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR), respectively, to evaluate their potential as diagnostic biomarkers for BSIs. Blood cultures were performed to confirm infections and identify pathogens.ResultsThe BSIs group showed significantly lower CGRP and PD-L1 levels, and higher PD-1 expression and PD-1/PD-L1 ratios compared to the non-BSIs group (all P < 0.001). Receiver operating characteristic (ROC) curve analysis showed area under the curve (AUC) values of 0.84 for CGRP, 0.77 for PD-1, 0.70 for PD-L1, and 0.86 for the PD-1/PD-L1 ratio. Combined detection achieved an AUC of 0.96, with 88% sensitivity and 92% specificity. Gram-negative bacteria (59.8%) were the predominant pathogens, with Escherichia coli (29.3%) being the most common.ConclusionCGRP alone showed strong diagnostic utility, but combining CGRP, PD-1, and PD-L1 markedly enhanced accuracy. ELISA and qPCR detection of these markers provides results within hours, enabling earlier diagnosis than conventional blood cultures.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251342877"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Time Matters: A Review of Current Radiotherapy Practices and Efficiency Strategies.","authors":"Sibel Karaca, Meltem Kırlı Bölükbaş","doi":"10.1177/15330338251345376","DOIUrl":"10.1177/15330338251345376","url":null,"abstract":"<p><p>Radiotherapy is a multi-step process that includes planning, contouring, simulation, patient assessment, quality control, and treatment. Each step must be completed before moving on to the next. Numerous factors, including patient characteristics, disease type, management, radiotherapy personnel, equipment, treatment modality, and total/fractional doses, affect the overall duration of radiotherapy. Time is one of life's most valuable resources and should be well managed and utilized. In radiotherapy, eliminating factors that unnecessarily prolong the treatment period significantly benefits the institution, patient, and staff. This review article examines the variables that affect overall treatment time in current external beam radiotherapy routines and offers suggestions for reducing treatment time.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251345376"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martina Ferioli, Alessandra Arcelli, Savino Cilla, Arina A Zamfir, Giorgio Tolento, Dajana Cuicchi, Milly Buwenge, Erika Galietta, Bruno Fionda, Luca Tagliaferri, Matteo Rottoli, Gilberto Poggioli, Alessio G Morganti
{"title":"Electrochemotherapy for Anorectal Tumors: A Narrative Literature Review.","authors":"Martina Ferioli, Alessandra Arcelli, Savino Cilla, Arina A Zamfir, Giorgio Tolento, Dajana Cuicchi, Milly Buwenge, Erika Galietta, Bruno Fionda, Luca Tagliaferri, Matteo Rottoli, Gilberto Poggioli, Alessio G Morganti","doi":"10.1177/15330338251349596","DOIUrl":"10.1177/15330338251349596","url":null,"abstract":"<p><p>This narrative review explores the potential role of electrochemotherapy (ECT) in treating anorectal tumors, focusing on its effectiveness, feasibility, and associated toxicities. ECT, which combines chemotherapy with the application of an electric field to enhance drug uptake by tumor cells, has shown promise as a local treatment, particularly in cases where conventional therapies such as radiotherapy have been exhausted or are unsuitable. The review, conducted according to SANRA guidelines, included 18 studies, on ECT in anorectal tumors, ranging from preclinical trials in dogs to case reports and clinical studies in humans. The findings indicate that ECT can achieve high tumor overall response rates (70-100%) with minimal side effects, offering benefits such as tumor reduction and preserved organ function. These results highlight the potential of ECT to provide not only tumor reduction but also the preservation of vital organ function with a relatively low toxicity profile. However, further comparative research is necessary to substantiate its role as a standard therapeutic option. Moreover, the evidence is limited by significant heterogeneity across studies, small sample sizes, and a lack of comparative research with other local treatments like radiotherapy and cryosurgery. Consequently, while ECT appears to be a promising option, particularly for palliative care or in a neoadjuvant setting, it cannot yet be recommended as a standard treatment. Future research should focus on larger, more robust studies with standardized outcomes and explore the potential synergy between ECT and other therapies to establish its place in the treatment of anorectal tumors.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251349596"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}